Dr. Andrew B. Lassman, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 17
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Columbia University College of Physicians and Surgeons
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 210850
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 17
- Services billed
- 88
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $5,314 in total to this clinician.
| Rigel Pharmaceuticals, Inc. | $4,550 |
|---|---|
| Deciphera Pharmaceuticals Inc. | $675 |
| Servier Pharmaceuticals LLC | $88.92 |
| Consulting Fee | $4,550 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $675 |
| Food and Beverage | $88.92 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Rigel Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $1,625 |
| Rigel Pharmaceuticals, Inc. Apr 25, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $1,625 |
| Deciphera Pharmaceuticals Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $675 |
| Rigel Pharmaceuticals, Inc. Jul 25, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $650 |
| Rigel Pharmaceuticals, Inc. Sep 15, 2025 | Consulting Fee TAVALISSE; Rezlidhia; Gavreto · Hematology | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $27,233 in research payments for these studies, mostly to the institutions running them.
- Study of vorasidenib, AG-881, in participants with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation, indigo
Servier Bioinnovation - A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Act…
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.